Experts to advance precision cardiovascular medicine in China

23 November 2015

The group for precision cardiovascular medicine was established with the Chinese Society of Cardiology on Sunday in Nanjing, east China's Jiangsu Province, committed to advance precision medicine for cardiovascular disease (CVD) in China, reports Xinhau, the Chinese state news agency.

The Chinese Society of Cardiology is part of the Chinese Medical Association, the largest non-governmental medical organization in China. The group plans a database of monogenic inherited CVD and cardiovascular pharmacogenomics for Chinese and to map genetic variation by recruiting volunteer patients nationwide.

It also aims to facilitate the basic research of precision cardiovascular medicine advancing towards clinical application, and to help the government to roll out regulations and standards for CVD molecular screening and diagnostics.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >